Large volume fat grafting is limited by unpredictable volume loss; therefore, methods of improving graft retention have been developed. Fat graft enrichment with either stromal vascular fraction (SVF) cells or adipose tissue-derived stem/stromal cells (ASCs) has been investigated in several animal and human studies, and significantly improved graft retention has been reported. Improvement of graft retention and the feasibility of these techniques are equally important in evaluating the clinical relevance of cell enrichment. We conducted a systematic search of PubMed to identify studies on fat graft enrichment that used either SVF cells or ASCs, and only studies reporting volume assessment were included. A total of 38 articles (15 human and 23 animal) were included to investigate the effects of cell enrichment on graft retention as well as the feasibility and clinical relevance of cell-enriched fat grafting. Improvements in graft retention, the SVF to fat (SVF:fat) ratio, and the ASC concentration used for enrichment were emphasized. We proposed an increased retention rate greater than 1.5-fold relative to nonenriched grafts and a maximum SVF:fat ratio of 1:1 as the thresholds for clinical relevance and feasibility, respectively. Nine studies fulfilled these criteria, whereof 6 used ASCs for enrichment. We found no convincing evidence of a clinically relevant effect of SVF enrichment in humans. ASC enrichment has shown promising results in enhancing graft retention, but additional clinical trials are needed to substantiate this claim and also determine the optimal concentration of SVF cells/ASCs for enrichment.
Interest in improving fat graft retention by enriching the grafts with stromal vascular fraction (SVF) cells or adipose tissue-derived stem/stromal cells (ASCs) has burgeoned over the past decade because fat grafting is impeded by low graft survival and resorption, leading to unpredictable results and repetitive procedures. [1] [2] [3] [4] Resorption rates in conventional fat grafting range from 25% to 80%, [5] [6] [7] [8] with an inverse correlation between the survival and the volume of the fat graft. 1 This implies a challenge when large volumes of fat are grafted (ie, during breast reconstruction or augmentation).
To enhance graft retention, enrichment of the fat graft with cells either from the adipose tissue derived SVF or with ex vivo expanded ASCs have been suggested. Numerous studies in both animals and humans have explored both types of enrichment, 2, 4, 8, 9 and some have shown promising results. Significant improvement in graft retention of enriched large volume fat grafts will have broad clinical implications; however, the future applicability of SVF/ASC enrichment is not only determined by the increase in fat graft retention itself but also by the clinical feasibility of the technique. Therefore, we have systematically reviewed the literature to present evidence of the clinically relevant effects of SVF/ASC enrichment as well as the clinical feasibility of these techniques relevant in large volume fat grafting.
Stromal Vascular Fraction
The SVF is obtained from collagenase-digested fat tissue and comprises a heterogeneous cell population that includes cells of endothelial, hematopoietic, and pericytic origin as well as a minor fraction of ASCs (less than 3%). 10, 11 Many of these cells may play a role in SVFenriched fat grafting, but using the term "adipose stem cells" does not accurately reflect the SVF cell population.
Adipose Derived Stem/Stromal Cells
ASCs are derived from mesenchymal stem/stromal cells (MSCs), which are multipotent progenitor cells that were initially discovered in the bone marrow as support for hematopoiesis. 12 In past decades, ASC populations have additionally been identified in several other adult and fetal tissues. Adipose tissue is a rich source of MSCs, 8, 9, 13 but despite containing more than 500-fold more MSCs than adult bone marrow, MSCs still require ex vivo expansion when used for research and/or clinical applications to obtain a sufficient number of cells. 11, 13, 14 In the cell-enriched fat grafting setting, MSCs from adipose tissue are the most biologically obvious choice as a source because the acquired ASCs are distributed into their tissue of origin.
Role of ASCs in Fat Grafting
Fat graft survival initially depends on nutritional diffusion until revascularization occurs. Experimental models of initial fat graft behavior have defined three zones: (1) a peripheral, regenerating zone; (2) an intermediate, inflammatory zone; and (3) a central, necrotic zone. 15 Although the viability of tissues in the intermediate zone may be preserved, the diffusion of nutrients to the central zone is insufficient, resulting in necrosis and graft resorption. ASCs have been proposed to help increase graft survival and ultimately graft retention by several different mechanisms, including differentiation into mature adipocytes, 15, 16 endothelial cell formation plus neoangiogenesis, 17, 18 and the release of angiogenic growth factors in response to hypoxia. [17] [18] [19] [20] During liposuction, more than 30% of the harvested mature adipocytes and up to 50% of adipose tissue progenitors are lost due to both mechanical disruption and the fact that progenitor cells are mostly localized in the perivascular regions of midsize and large vessels, which are generally spared during liposuction. [21] [22] [23] Based on this observation, enrichment with supplemental ASCs (either as SVF cells or as ex vivo expanded ASCs) to increase fat graft retention and survival has been introduced. However, the efficiency of cell-enriched fat grafts under clinical conditions remains heavily debated, and investigators have reported results that both support and contradict these procedures. 24, 25 
METHODS
The PRISMA 26 guidelines for systematic reviews were followed when applicable.
Search Strategy
A systematic search for studies published between January 2000 and November 2016 on cell-enriched fat grafting with either SVF cells or ASCs was conducted using the PubMed database in November 2016 with the following search strategy: ("mesenchymal stem cells" OR "mesenchymal stromal cells" OR "adipose stem cells" OR "processed lipoaspirate" OR "pre-adipocytes" OR "stromal vascular fraction" OR "adipose-derived stem cells" OR "adipose-derived stromal cells" OR "adipose-derived regenerative cells" OR "adipose tissue-derived stromal cells" OR "adipose tissue-derived stem cells" OR ADRC OR ASC OR hASC OR MSC OR ADSC) AND ("cell-assisted lipotransfer" OR "lipofilling" OR "fat grafting" OR "fat transplantation" OR "fat graft"). This search was independently performed by two of the authors (B.S.R. and C.L.S.).
Study Selection
Two independent reviewers (B.S.R. and C.L.S.) screened the abstracts and full texts of the articles. Review articles and non-English language articles were excluded. The eligibility criteria were controlled human and animal studies and noncontrolled human studies of fat grafting with either SVF cell or ASC enrichment where an assessment of the volume was reported.
The primary scope of this review was to elucidate the clinically relevant effects on graft retention and the clinical feasibility of cell enrichment relevant to large volume fat grafting. Hence, in the initially identified human studies on SVF enrichment, only those on breast reconstruction or augmentation were included. For ASC enrichment, only two human studies exist, both of which were included for comparison because they provide information regarding volume retention and cell dosage despite neither of them involving breast reconstruction or augmentation.
Data Acquisition
Due to the highly heterogeneous nature of the included studies, we concluded that a meta-analysis was inapplicable. Instead, the studies were divided into 4 groups according to species (human or nonhuman) and the type of enrichment (SVF cells or ASCs) (Tables 1-4) for analysis. The following parameters were noted for the included studies: study design and application, graft volume, volume assessment, cell enrichment dose, relative retention rate, graft retention, and the SVF:fat ratio (as defined by the volume of fat used for isolation of SVF cells relative to that used for grafting). In the animal studies, we also calculated an "estimated SVF:fat ratio" to establish a realistic SVF:fat ratio when the data were extrapolated into a clinical setting and to further evaluate the clinical feasibility and relevance of SVF enrichment in these studies.
RESULTS
The search strategy provided 232 articles. Abstract screening identified 58 articles of potential relevance, and after the full texts were read, 38 articles were included in the review (Figure 1 ). Reference lists of the included papers were also checked for additional papers of relevance, but none were found. There were also no disagreements in selecting the articles.
The 38 studies were divided into 4 groups. The human studies were categorized by enrichment of fat grafts with SVF cells (n = 13) and enrichment of fat grafts with ex vivo expanded ASCs (n = 2); the animal studies were categorized by enrichment of fat grafts with SVF cells (n = 13) and enrichment of fat grafts with ex vivo expanded ASCs (n = 11). One animal study used both SVF cells and ASCs. 38 ( MRI, magnetic resonance imaging; NCT, non-randomized controlled trial; NS, not significant; PRP, platelet-rich plasma; SVF, stromal vascular fraction. * The relative retention rate states the graft retention of the SVF-enriched fat graft relative to that of the control graft. ** Actual graft retention relative to the initial volume injected. 
Human Studies: Enrichment of Fat Grafts With SVF Cells

Controlled Studies
Five controlled studies using SVF-enriched fat grafting reported objective volume assessment. 3, [29] [30] [31] 35 Three of these examined SVF-enriched fat grafting in cosmetic breast augmentation, 3, 29, 35 whereas the other 2 examined SVF-enriched fat grafting in breast reconstruction. 30, 31 The SVF:fat ratios used were 0.5:1, 1:1, and 2:1 (Table 1) . Only the 2 studies on breast reconstruction reported significantly increased graft retention for SVF-enriched fat grafts relative to controls, 30, 31 and both of these studies used an SVF:fat ratio of 1:1. Approximately 63% of the grafts were successfully retained in the SVF group vs 39% in the control group in both studies. 30, 31 One of these 31 compared 4 different automated devices for SVF isolation and found a relative retention rate ranging from 1.00 to 1.62. In this study, however, each patient underwent 2 full sessions of fat grafting under general anesthesia. Of the remaining 3 studies reporting an objective volume assessment, 2 indicated no significant differences in fat graft retention between the SVF and control groups, 3, 35 whereas one suggested an improvement in graft retention with the use of SVF cells at a ratio of 0.5:1; however, no P value was stated. 29 One last controlled study that did not use objective volume assessment evaluated the effect and feasibility of SVF enrichment using 3 different automated devices for SVF extraction. 28 Fat graft retention was assessed by ultrasonography, and the results favored the SVF group. However, the volume assessment was not objective, and the mean size of the grafts in the 2 groups were significantly different (143 and 95 mL in the SVF and control groups, respectively).
Uncontrolled Studies
Three uncontrolled studies 7, 32, 37 performed SVF enrichment in breast augmentation with a graft approximately 250 mL in size per breast. Magnetic resonance imaging (MRI) 7,32 and 3-dimensional photography 37 were used for objective volume assessment. The SVF:fat ratios used were 0.33:1, 0.5:1, 7,32 or not stated, 37 and the graft retention for the three studies was 53%, 51%, and 56%, respectively.
Additionally, 4 uncontrolled studies performed SVFenriched fat grafting and suggested improvement in graft retention but only subjectively quantified graft retention. 27, 33, 34, 36 Human Studies: Enrichment of Fat Grafts With ex vivo Expanded ASCs Table 2 summarizes the 2 human studies that used fat grafts enriched with ex vivo expanded ASCs.
One study demonstrated fat graft enrichment using autologous ex vivo expanded ASCs in a randomized, blinded, placebo-controlled trial. Patients (n = 10) received 30 mL of fat grafts in the subcutaneous layer on each upper arm: one graft consisting of fat enriched with 2 × 10 7 ASC/mL, and the other serving as a control with fat alone. A 4-month follow-up showed that the ASCenriched fat grafts had significantly higher graft retention (81% vs 16%) as quantified by MRI. 6 The other study involved facial fat grafting with either fat alone or fat enriched with 1 × 10 7 ASCs/mL. At the 6-month follow-up, 3D computed tomography (CT) CT, computed tomography; DMEM, dulbecco's modified eagle's medium; VEGF-PLA, vascular endothelial growth factor-polylactic acid; GV, initial graft volume; NS, not significant; RT, randomized trial; SVF, stromal vascular fraction. * Estimated SVF yield: 500.000 SVF/ml fat. ** The relative retention rate states the graft retention of the SVF-enriched fat graft relative to that of the control graft. *** Actual graft retention relative to the initial volume injected. Three-armed, RT. Control group. GV: 0.8 mL 7.5 × 10 6 P 4 1.6 Weight At 3 months: 1) Fat alone + DMEM: 45.0%, 2) 6 × 10 6 Syngeneic ASCs: 70% P < 0.01 3) 6 × 10 6 Allogeneic ASCs: 66.8% P < 0.01 ASC, adipose tissue-derived stem/stromal; bFGF, fibroblast growth factor; CXCR4-ASC, C-X-C chemokine receptor type 4; E2, estradiol; GV, initial graft volume; NS, not significant; P, stem cell passage; PRP, platelet-rich plasma; RT, randomized trial; SVF, stromal vascular fraction. * The relative retention rate states the graft retention of the ASC-enriched fat graft relative to that of the control graft. ** Actual graft retention relative to the initial volume injected.
indicated that ASC-enriched grafts exhibited significantly higher graft retention (79% vs 53%). However, the average injected volume was 12.5 mL in the control group vs 29.9 mL in the ASC group. 38
Animal Studies: Enrichment of Fat Grafts With SVF Cells
Thirteen animal studies using xenogeneic, allogeneic, or autologous cells and transplants have been conducted to investigate the fate and graft retention of SVF-enriched fat grafts. 17, 18, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] The relevant study information is listed in Table 3 . In addition, Table 5 shows the correlation between the estimated SVF:fat ratio and the relative retention rate. All studies were placebo controlled, and all but one reported significantly higher graft retentions ranging from a 0.65 to a 2.5-fold improvement compared to fat alone after a mean follow-up of 13 weeks (range, 4-36 weeks) ( Table 3) .
Most studies quantified the graft retention by surgical excision and weight/fluid displacement. Three studies used CT or bioimaging. All the studies used very small graft volumes (range, 0.1-1 mL) and a bolus/en bloc grafting technique.
Cell counts were used to quantify the magnitude of the enrichment in nine studies, 18,39,40,42-44,47-49 the SVF:fat ratio 17, 41, 46 was used in three studies, and one study did not specify the magnitude of graft enrichment. 45 The number of SVF cells used for enrichment ranged from 5 × 10 4 to 5 × 10 7 SVF cells/mL, and the reported SVF:fat ratios varied between 0.02:1 and 167:1 (Table 3) .
Three studies investigated the effect of different SVF cell concentrations on the grafts, 42, 46, 47 and these studies found that the lowest concentrations used (3 × 10 5 , 5 × 10 4 SVF cells/mL and SVF:fat ratio 0.17:1) were associated with the most graft retention and the best graft morphology.
Four of the 5 studies that performed a systematic histological examination of the explanted fat grafts found improved graft morphology in terms of integrity as well as reduced cyst formation and fibrosis in the SVFenriched grafts. 42, 44, [47] [48] [49] All remaining studies except one 40 additionally described improved morphology, but the methods used to analyze the morphology were not clearly specified.
Fat harvest by excision and manual isolation enhances the SVF yield 4,22 but hardly has any clinical relevance. Therefore, automated isolation systems such as the GID system, the Tissue Genesis Cell Isolation System, and the Celution800/CRS have emerged, with reported SVF yields of approximately 720,000, 700,000, and 350,000 SVF cells/ mL of processed fat, respectively. All these devices report a viability of approximately 80%. 27, 50, 51 To establish a realistic SVF:fat ratio when translating these methods into a clinical setting, we chose to use an average of 500,000 live SVF cells/mL of fat for the "estimated SVF:fat ratio" column in Tables 3 and 5 . In some of the studies, no specific yield was noted; thus, we used the SVF:fat ratio as stated by the authors.
Animal Studies: Enrichment of Fat Grafts With ex vivo Expanded ASCs
Eleven animal studies using ex vivo expanded ASCs were included in this review. 22, 45, [52] [53] [54] [55] [56] [57] [58] [59] [60] Xenogeneic, allogeneic, and autologous cells and transplants were used (Table 4) . Table 6 shows the correlation between the concentration of ASCs used for enrichment and the relative retention rate.
All the studies were placebo controlled, and 8 studies reported a significant improvement in the retention of grafts enriched with ASCs compared to that of control grafts; this improvement ranged from 1.2-to 2.4-fold. Two studies did not demonstrate a significantly positive effect of ASC enrichment, 45, 53 and one study reported a relative retention rate of 4.1 but did not perform statistical analyses. 56 The mean follow-up was 14 weeks (range, 12-26 weeks).
ASCs were characterized by either flow cytometry or differentiation studies and were cultured to passages 2, 3, or 4 in all included studies.
The concentration of ASCs used for enrichment in these studies varied between 1 × 10 4 and 1.67 × 10 7 ASCs/mL of fat graft. Two studies further investigated the effect of different concentrations of ASCs; one study found improved graft retention with a concentration 1 × 10 5 ASCs/mL, 54 and the other study observed no significant improvement using ASC-enriched cryopreserved lipoaspirates. 53 All studies except one conducted histological analyses of the explanted grafts. Only 3 studies did so systematically, 2 of which observed a significant improvement in graft morphology (ie, decreased necrosis, fibrosis, and cyst formation as well as more viable adipocytes) when using ASCs. 57, 60 The remaining studies described an improvement in graft morphology when using ASCs but did not provide sufficient descriptions of the methods or the statistics used to substantiate these claims.
DISCUSSION
In this review, we chose to focus not only on the efficacy of cell enrichment but also on the feasibility and clinical relevance of cell enrichment in the specific application of large volume fat grafting, which constitutes a major clinical challenge and may benefit the most from SVF/ASC enrichment. It is therefore important for physicians to decide whether cell enrichment is more beneficial than repetitive procedures of conventional nonenriched fat grafting.
Recently, published reviews concluded that cell enrichment has shown promising results in improving fat graft retention. 24, 25 A meta-analysis conducted by Zhou et al 25 provided interesting knowledge on cell enrichment but did not distinguish between SVF cell and ASC enrichment, as all the data were "pooled." Two important issues should be addressed in this respect. First, SVF cells and culture-expanded ASCs represent 2 highly diverse cell populations with vast differences in cell composition. Second, the number of ASCs per mL of enriched fat graft is variable between the two types of enrichment. The percentage of ASCs in an SVF preparation is reported to be approximately 3%, 10, 11 which means that a concentration of approximately 1.5 × 10 4 ASCs per mL is achieved with the use of a SVF:fat ratio of 1:1. This equals a doubling in the physiological number of ASCs in fat tissue. However, the 2 human studies that used culture-expanded ASCs reported concentrations of 1 × 10 7 and 2 × 10 7 ASCs per mL, respectively 6,38 which corresponds to an increase of up to 2000 times the physiological number of ASCs in fat tissue.
Cell enrichment in fat grafting is only relevant if it provides a substantial improvement in graft retention and ensures that only one major surgical procedure is required for the desired result. Interestingly, Zhou et al 25 reported that compared to nonenriched fat grafting, SVF enrichment could not improve graft retention to an extent where fewer surgical procedures were necessary.
In our evaluation of the clinical relevance of cell enrichment in fat grafting, we proposed a limit for minimal improvement in graft retention of 1.5-fold relative to a nonenriched fat graft. When this criterion was applied to the included studies, only 15 of the 38 studies demonstrated this magnitude of improvement. Among these 15, eight were studies using SVF enrichment (3 human, 5 animal), and 7 used ASC enrichment (2 human, 5 animal).
Cell enrichment should not merely be efficacious in improving graft retention but also clinically feasible. Because the lipoaspirate is the source of both the graft itself as well as the SVF cells, the supply of fat can become restrictive both in the patient selection and in large volume fat grafting, where SVF:fat ratios of 1:1 or greater can be challenging. Among the animal studies that showed an improvement in graft retention greater than 1.5-fold relative to the control group, only 2 used a clinically feasible SVF:fat ratio of 1:1 41, 42 (Table 5 ). Additionally, 2 human studies met the criteria 30 for minimal relevant improvement in graft retention (1.5-fold increase) compared to the control group. However, in one of these studies, patients underwent 2 full surgical fat grafting sessions under general anesthesia, which arguably reduces the clinical relevance. 31 Regarding ASC enrichment, 5 animal studies showed a statistically significant improvement greater than 1.5-fold relative to the control; interestingly, 4 of them used concentrations greater than 5 × 10 6 ASCs/mL of fat. The 2 studies using the highest concentrations (1 × 10 7 and 1.67 × 10 7 ASCs/mL) obtained the best graft retention, with increases of 2.2 and 2.4-fold compared to fat alone. 55, 58 This indicates that there might be a positive correlation between the concentration of ASCs and graft retention (Table 6 ).
In one human study that used 2 × 10 7 ASCs/mL and a bolus injection of 30 mL, the graft retention was 5 times that of the control graft. 6 Although the fat grafts were injected as a bolus, the study demonstrated a convincing effect of a high concentration of ASC enrichment even in a "worst case scenario" (ie, bolus injection). Compared to bolus injection, structural fat grafting 61 provides superior graft retention, but in large volume fat grafting, the droplets/aliquots may coalesce into larger globules that could negatively impact the overall retention. 24 This is a challenge that ASC enrichment might alleviate in the future.
The other human study on ASC enrichment also reported a clinical relevant relative graft retention of 1.5-fold compared to nonenriched fat grafting. However, the mean graft volume varied considerably between the control and ASCenriched grafts with the latter being significantly larger. This discrepancy could arguably underestimate the beneficial effect of the ASC enrichment. 38 Comparing cell-enriched graft retention with that of a nonenriched control is important when evaluating the efficacy of these techniques. However, with respect to the clinical relevance, the actual graft retention (which is relative to the initially grafted volume) is even more essential. Cell enrichment must provide a substantial improvement in actual graft retention for not being deemed unpredictable and require the need of overcorrection and repeated procedures. In this respect, human studies using SVF cells reported somewhat disappointing actual graft retentions with an average of 61% (range, 50%-79%) (Table 1) . However, the 2 human studies using ASCs 6, 38 reported an average actual graft retention of 80% (range, 79%-81%), which is indeed promising, especially considering that one study used a grafting procedure known as a "worst case scenario" (ie, bolus injection) 6 (Table 2) .
SVF Cells vs ASCs: Pros and Cons
The major advantage of using SVF enrichment compared to ex vivo expanded ASCs is that this procedure is a point of care procedure because using one of the several automated devices available eliminates the requirement for a large laboratory set-up. 31 However, the fat supply can be a natural restriction in large volume fat grafting. To date, no existing studies have convincingly demonstrated that SVF enrichment can secure comparable or improved graft retention vs what can be achieved in 2 sessions of conventional fat grafting. 62 Thus, repetitive procedures could still be necessary. This is compounded with the challenge of the restricted fat supply. Finally, SVF cells comprise a highly heterogeneous cell population, and the composition of the SVF, the number of ASCs, and the activity of these cells can vary greatly among patients, all of which could contribute to the unpredictable nature of SVF enrichment.
In contrast to the multiple clinical SVF studies, only 2 clinical studies on ASC enrichment exist. Ex vivo expanded ASCs provide a large and relatively homogenous cell population from a small volume of lipoaspirate, which eliminates the competition for resources with other cells from the SVF within the hypoxic postgrafting environment and provides a better chance for the ASCs (and grafted adipocytes) to survive. 43, 47 Additionally, another advantage of ASCs is that the fat volume required for sufficient ASC propagation is markedly less than that of SVF cells because ASCs can be expanded in culture. The small amount of fat needed to isolate ASCs can easily be obtained under local anesthesia. This is advantageous in patients with low body mass indexes or if repetitive procedures are necessary for any reason.
However, the use of ex vivo expanded ASCs requires a highly cumbersome set-up. Culturing ASCs for clinical use is subject to strict regulatory requirements and demands a relatively large laboratory setup that meets "good manufacturing practices" regulations. This inevitably will raise the costs and is not feasible for most private practices. Additionally, culturing the cells takes approximately 3 weeks, which results in a prolonged total treatment time.
The optimal concentration of either SVF cells or ASCs used for enrichment is currently unknown. Two animal studies investigated the effect of different concentrations of SVF cells in enriched grafts and found that the lowest concentrations used (3 × 10 5 and 5 × 10 4 SVF cells/ mL) rendered not only the best graft retention but also the best graft morphology, and the use of higher concentrations led to a significant deterioration in morphology. 42, 47 Conversely, histological evaluation in studies with ASC enrichment reported graft morphology of the enriched fat grafts similar to that of normal fat tissue regardless of the ASC concentration used. 6, 54, 57 
Safety of Cell Enrichment
The safety of stem cell-enriched fat grafting in the breast is a widely debated topic. Although the literature is characterized by a remarkable discrepancy concerning tumor-promoting effects of SVF cells and ASCs, it is widely recognized that neither of these cells themselves evolve into malignant cells. Additionally, to the best of our knowledge, no patient treated with either SVF cells or expanded ASCs has been subsequently reported to suffer from SVF/ASCrelated tumor formation. However, the long-term safety of SVF/ASC-enrichment has yet to be scrutinized. 13, 63 
Limitations of This Review
The scientific quality of the included studies varied significantly which is why a comparative analysis would be inaccurate, and due to the heterogeneity of the studies, we determined that a meta-analysis was beyond the scope of this review. Instead, we performed separate subgroup, analyses although this hampers our ability to make a generalized conclusion on the subject. We also suggested arbitrary (but in our opinion, relevant) cut-off values for minimal clinically relevant improvement in enriched graft retention as well as for a feasible SVF:fat ratio. Although these cut-off values are subjective, we found that both values were important when evaluating the clinical relevance of cell-enriched fat grafting. By focusing on large volume fat grafting, numerous studies on breast reconstruction/augmentation with SVF enrichment were included; however, there are no studies on the use of expanded ASCs in large volume fat grafting for comparison. Only one human study on facial reconstruction 38 and one randomized clinical trial with fat grafts on the upper arms 6 exist. Despite this, we believe that the inclusion of these alternative studies is important and hope that future clinical studies of ASC enrichment will further contribute to the investigation of the potential differences between SVF and ASC enrichment.
CONCLUSION
Segregating the studies that use SVF cells from those that use ex vivo expanded ASCs for fat graft enrichment is paramount as the cellular composition and concentration between these populations differ greatly, rendering the studies incomparable.
To date, most studies on small animals show an isolated beneficial effect on fat graft retention upon enrichment by either SVF cells or ASCs. However, only a minority of the SVF animal studies (2 of 13) are relevant when extrapolating to the clinical setting of large volume fat grafting due to either the sparse improvement in graft retention or an unrealistically high SVF:fat ratio. In contrast, we believe that five of the 11 animal studies that used ASCs are clinically relevant in terms of improving graft retention. These studies also showed a tendency of a positive correlation between the concentration of ASCs used and the level of graft retention.
We found that most of the human studies of SVF-enriched fat grafting were of low scientific quality. The applied techniques for cell extraction and the reported cell concentrations were highly heterogeneous, and the results were contradictory. In our opinion, the efficacy of SVF enrichment in humans is unconvincing when reviewing the current literature because when applying our proposed minimum level of increase in graft retention with a feasible SVF:fat ratio, only one study reported results of clinical relevance.
In contrast, the 2 human studies of ASC-enriched fat grafting report clinically relevant increases in graft retention of 1.5-fold or above, and of all the studies on cell enrichment in fat grafting to date, the most consistent effect on graft retention was demonstrated in a randomized, blinded, placebo-controlled clinical trial using ASC enrichment at the highest concentration ever reported. 6 However, these results require further investigation in a more relevant clinical setting of large volume fat grafting.
Future clinical trials should also try to determine the ideal practice and the optimal concentration of SVF cells or ASCs used for enrichment as this is necessary to provide a gold standard for cell-enriched fat grafting.
